Zhu Ke-Fu, Li Hai-Jin, Qiao Chuan-Fu, Wang Liu-Fang, Wu Pei-Jing, Chen Ying, Tian Xin
Department of Hematology and Oncology, Kunming Children's Hospital/Children's Hospital Affiliated to Kunming Medical University, Kunming 650228, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2024 Jul 15;26(7):708-715. doi: 10.7499/j.issn.1008-8830.2312152.
To investigate the expression of CD123 in children with acute lymphoblastic leukemia (ALL) and its effect on the clinical characteristics and prognosis of children with B-lineage acute lymphoblastic leukemia (B-ALL).
A retrospective analysis was conducted on the clinical data of 251 children with ALL who were admitted to the Department of Hematology and Oncology, Children's Hospital of Kunming Medical University, from December 2019 to June 2022. According to the expression of CD123 at initial diagnosis, the children were divided into CD123 group and CD123 group, and the two groups were compared in terms of clinical characteristics and treatment outcome. The factors influencing the prognosis were analyzed.
Among the 251 children with ALL, there were 146 children (58.2%) in the CD123 group. The B-ALL group had a significantly higher positive expression rate of CD123 than the acute T lymphocyte leukemia group (<0.05). Compared with the CD123 group, the CD123 group had significantly lower peripheral blood leukocyte count and percentage of juvenile cells and a significantly higher proportion of children with high hyperdiploid karyotype or an age of 1-10 years, with a relatively low proportion of children with fusion gene (<0.05). The multivariate Cox proportional-hazards regression model analysis showed that compared with the >10 years group, the 1-10 years group had a significantly higher overall survival rate (<0.05), and compared with the high risk group, the moderate risk group had a significantly higher event-free survival rate in children with B-ALL (<0.05).
CD123 is widely expressed in children with B-ALL, and positive expression of CD123 might be an indicator for good prognosis in children with B-ALL, which is of great significance for evaluating the efficacy of remission induction therapy and survival prognosis of children with B-ALL.
探讨CD123在急性淋巴细胞白血病（ALL）患儿中的表达及其对B系急性淋巴细胞白血病（B-ALL）患儿临床特征及预后的影响。
回顾性分析2019年12月至2022年6月昆明医科大学附属儿童医院血液肿瘤科收治的251例ALL患儿的临床资料。根据初诊时CD123的表达情况将患儿分为CD123阳性组和CD123阴性组，比较两组的临床特征及治疗结局，并分析影响预后的因素。
251例ALL患儿中，CD123阳性组有146例（58.2%）。B-ALL组CD123阳性表达率明显高于急性T淋巴细胞白血病组（<0.05）。与CD123阴性组相比，CD123阳性组外周血白细胞计数及幼稚细胞百分比明显更低，高超二倍体核型或年龄110岁的患儿比例明显更高，融合基因阳性患儿比例相对更低（<0.05）。多因素Cox比例风险回归模型分析显示，与>10岁组相比，110岁组总生存率明显更高（<0.05），与高危组相比，中危组B-ALL患儿无事件生存率明显更高（<0.05）。
CD123在B-ALL患儿中广泛表达，CD123阳性表达可能是B-ALL患儿预后良好的指标，对评估B-ALL患儿缓解诱导治疗疗效及生存预后具有重要意义。
